Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older

Japanese Journal of Clinical Oncology

Volumn 41, Issue 1, 2011, Pages 76-80

  Yukisawa, Seigo ^a   Ishii, Hiroshi ^a   Matsuyama, Masato ^a   Kuraoka, Kensuke ^a   Takano, Koichi ^a   Kamei, Akira ^a   Ozaka, Masato ^b  

^a Cancer Institute Hospital   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Biliary cancer; Chemotherapy; Elderly patients; Pancreatic cancer

Indexed keywords

GEMCITABINE;

AGED; ANEMIA; ARTICLE; ASCITES; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHOLANGITIS; COMORBIDITY; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOCALCEMIA; ILEUS; INFECTION; INTERSTITIAL PNEUMONIA; LETHARGY; LEUKOPENIA; LIVER ABSCESS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PNEUMONIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; COMORBIDITY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650784217     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq160     Document Type: Article

References (12)

1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 2009;39:850-8.
2. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer 1994;74(Suppl. 7):2208-14.
3. Yonemori K, Hirakawa A, Komiyama N, Kouno T, Ando M, Fujiwara Y, et al. Participation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol. 2010 Mar 23. [Epub ahead of print].
4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
5. Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179-89.
6. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63.
7. Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 2008;61:369-77.
8. Furuse J, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008;15:55-62.
9. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
10. Furuse JMM, Taniai H, Nimura Y. A randomaized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. J Clin Oncol 2009;27(Suppl.):15s. abstract.
11. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
12. Marechal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008;36:16-21.